EXS4318
EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb.[1][2] In 2023, it entered clinical trials in humans.[3]
References
[edit]- ^ Philippidis, Alex (1 January 2023). "BMS Collaboration Paying Off for Exscientia: AI drug developer designs EXS4318, the I&I small molecule that has entered Phase I trials overseen by pharma giant in up-to-$1.3B+ partnership". GEN Edge. 5 (1): 147–150. doi:10.1089/genedge.5.1.31.
- ^ Arnold, Carrie (1 June 2023). "Inside the nascent industry of AI-designed drugs". Nature Medicine. 29 (6): 1292–1295. doi:10.1038/s41591-023-02361-0. ISSN 1546-170X.
- ^ "BMS in-licensed PKC theta inhibitor enters clinical trials". European Pharmaceutical Review. Retrieved 4 November 2023.